For research use only. Not for therapeutic Use.
Zilovertamab (UC-961) is a humanised monoclonal antibody against ROR1 that blocks Wnt5a-induced ROR1 signalling[1].
Zilovertamab (25 and 50 µg/mL; 72 h) inhibits high-grade serous ovarian cancer (HGSOC) cell proliferation[1].
Zilovertamab (50 µg/mL; 72 h) down-regulates ROR1 expression levels in CaOV3 at the transcriptional level[1].
| Catalog Number | I042686 |
| Purity | ≥95% |
| Reference | [1]. Liu D, et, al. The Anti-ROR1 Monoclonal Antibody Zilovertamab Inhibits the Proliferation of Ovarian and Endometrial Cancer Cells. Pharmaceutics. 2022 Apr 11;14(4):837. |
